Join our ELITE global community of more than 2,500 members today!
Join more than 2,500 of your peers by staying ahead of the opportunities and obstacles impacting your corporate strategy with our most robust subscription option: Dual Access, a single-user, annual subscription to both MedTech Strategist and our newest industry publication, Market Pathways.
Interested in multi-user access? Click here to see if your company has access.
“The MedTech Strategist editorial team have been among the most insightful, impartial observers of the medical device world for decades. That clear vision and experience comes through in their in-depth articles which consistently identify important trends in our industry. I personally look forward to each new issue of MedTech Strategist.”
- Hanson S. Gifford, The Foundry, LLC
****
“The MedTech Strategist editorial team, through their publications and conferences, have become the preeminent source for medtech information and collaboration. They possess an unmatched combination of product/sector intelligence with access to the thought leaders and innovators at every stage of development, all of which is reflected in the MedTech Strategist.”
- Stan Rabinovich, Edwards Lifesciences
“We consider MedTech Strategist the leading publication in the medical technology arena. Given the intricacies and innovations in the industry, it is challenging to find impactful, well-researched and well-articulated content. Simply put, MedTech Strategist addresses all three. MedTech Strategist’s thoughtful analysis cuts through the noise and delivers what is most important to any medtech executive: insightful, and unbiased strategic thinking. It’s for these reasons that we routinely recommend MedTech Strategist to our management teams”
- Oded Ben-Joseph, PhD, Outcome Capital
****
“The MedTech Strategist editorial team have an encyclopedic knowledge of the Medical Device industry, and access to anyone and everyone in the field, from the start-up founder to the large corporate CEO. Their perspective on the trends and evolution of our sector is second to none, and I will continue to read the MedTech Strategist with real interest and pleasure.”
- Antoine Papiernik, Sofinnova Partners
